Cytokinetics CYTK Derivative, Gain (Loss) on Derivative, Net
Derivative, Gain (Loss) on Derivative, Net at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:DerivativeGainLossOnDerivativeNet.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's derivative, gain (loss) on derivative, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's derivative, gain (loss) on derivative, net?
- Cytokinetics (CYTK) reported derivative, gain (loss) on derivative, net of $1.5M in Q1 2026.
- How has Cytokinetics's derivative, gain (loss) on derivative, net changed year-over-year?
- Cytokinetics's derivative, gain (loss) on derivative, net increased by 475.0% year-over-year, from -$400K to $1.5M.
- What does derivative, gain (loss) on derivative, net mean?
- The net profit or loss from financial derivative contracts.
- How do you interpret derivative, gain (loss) on derivative, net?
- Gains indicate favorable market movements or effective hedging, while losses indicate unfavorable movements or hedging costs.
- How does derivative, gain (loss) on derivative, net compare across companies?
- Common in companies with significant international operations or complex capital structures involving hedging.